Cannabinoid-Terpene Composition for Chronic Pain and Opioid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods and compositions to manage chronic pain and treat opioid addiction, as existing treatments have limitations and contribute to the opioid crisis.
Innovation Solution
Pharmaceutical compositions comprising THC:CBD ratios of 1:1.5 to 3:1, combined with specific terpenes, formulated in various forms such as liquids, pills, capsules, transdermal patches, and inhalable forms, to alleviate chronic pain and reduce opioid use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioid medications are used to manage chronic pain, then pain relief is achieved, but opioid addiction and overdose risk increase
Solution Approach 1:
The patent changes the chemical parameters of the therapeutic composition by specifying precise ratios of cannabinoids (THC:CBD from 1:1.5 to 3:1 by weight) and incorporating specific terpenes (β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene) in defined concentrations. This parameter optimization aims to achieve effective pain management while reducing opioid dependency and overdose risk through a balanced cannabinoid profile that activates multiple endocannabinoid receptors and modulates pain pathways.
Solution Approach 2:
The patent creates a composite therapeutic composition combining multiple cannabinoids (THC and CBD) with specific terpenes in defined ratios. This composite approach leverages the synergistic effects of different cannabis compounds to achieve pain relief through multiple mechanisms simultaneously, reducing the need for high-dose opioids and associated harmful effects.
2Reliability
If high doses of THC are used for pain relief, then analgesic effect is improved, but psychoactive side effects and addiction potential increase
Solution Approach 1:
The patent optimizes the THC:CBD ratio parameter to fall within 1:1.5 to 3:1 by weight, preventing excessive THC dosing that causes psychoactive side effects. The inclusion of specific terpenes in defined concentrations further modulates the effects, maintaining analgesic activity while minimizing harmful psychoactive outcomes through pharmacological balance.
Solution Approach 2:
CBD and the specified terpenes act as intermediary substances that modulate THC's effects. CBD provides anti-anxious and anti-inflammatory properties that counterbalance THC's psychoactive effects, while terpenes like β-caryophyllene and linalool provide additional analgesic and anti-inflammatory actions, collectively reducing addiction potential and harmful side effects.
3Reliability
If multiple cannabis compounds are combined to enhance therapeutic effect, then treatment efficacy is improved, but formulation complexity increases
Solution Approach 1:
The patent simplifies the complex mixture of cannabis compounds by defining specific concentration parameters: THC:CBD ratio of 1:1.5 to 3:1 by weight, and specific terpene concentrations (β-myrcene: 30-60 mg, β-caryophyllene: 2.5-5 mg, ocimene: 2.3-4.7 mg, α-pinene: 1.1-2.1 mg, α-humulene: 0.8-1.6 mg per dose). This parameter specification provides clear manufacturing guidelines while maintaining the synergistic therapeutic effects of multiple compounds.
Data Source
AI summary
The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.